After Another NICE No, Will It Be Third Time Lucky For J&J's Spravato?

Market Access Process For Mental Health Product Proves Challenging

The healthcare giant's nasal spray for hard-to-treat depression has been rejected for use on the UK's NHS for a second time because of uncertainty over cost, but comments on this consultation could result in a change of fortunes for the potential blockbuster.

Target
J&J gets another go with NICE for Spravato • Source: Shutterstock

More from Drug Pricing

More from Scrip